UOM.MU Latvijas Juras centrs (MUN) volume spike pushes price -5.73% Mar 2026: €7.00 support seen

UOM.MU stock fell on a sharp intraday volume spike during market hours on 14 Mar 2026, trading at €7.40, down -5.73% from yesterday. The move came on 9,750 shares exchanged on the MUN (Germany) market and pushed price back toward the year low band. Investors should note the mismatch between a low market cap of €5,920,000.00 and steady operating metrics such as EPS €0.57 and P/E 12.98, which keep the name interesting for short-term traders watching volume-led breaks.

Price action and volume spike for UOM.MU stock

Today’s trade shows a clear volume spike: 9,750 shares traded versus an average volume baseline that registers effectively zero in the feed. The immediate price reaction was a €0.45 drop to €7.40, a -5.73% decline from the previous close of €7.85. This combination signals distribution during market hours and raises the importance of nearby support near €7.00.

Fundamentals and valuation snapshot

AS Latvijas Juras medicinas centrs trades on MUN (Germany) with a market cap of €5,920,000.00 and 800,000 shares outstanding. Key ratios: EPS €0.57, P/E 12.98, book value per share €8.55, and dividend per share €0.10. Relative to the Healthcare sector average P/E 29.42, UOM.MU stock looks inexpensive on headline multiples.

Technical signals and probable support-resistance

Short-term technicals are oversold: Bollinger lower band sits near €7.60 while the 50-day average is €8.44 and the 200-day average is €7.08. Momentum indicators show heavy downside pressure during the spike, and the daily range locked at €7.40 suggests low intraday liquidity. Traders should watch the €7.00 area as a high-probability support and €8.44 as the near-term resistance.

Meyka AI rates UOM.MU with a score out of 100

Meyka AI rates UOM.MU with a score out of 100: 72.01 | Grade B+ | Suggestion: BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Company rating data (date 2026-03-09) shows mixed signals: rating B- from one provider and neutral analyst recommendation, so investors should balance the Meyka grade with third-party views. These grades are not guaranteed and we are not financial advisors.

Catalysts, risks and sector context

Catalysts include stable EPS growth (latest EPS growth 13.43% year over year) and low leverage (debt to equity 0.00). Risks: thin liquidity reflected in extreme relative volume and a current ratio below 1.00 at 0.86, which could magnify price moves. Healthcare sector trends in Germany show modest YTD weakness, making sector rotation a headwind for small caps like UOM.MU stock.

Trading and volume-spike strategy for UOM.MU stock

Given the volume spike and tight float, short-term traders may use a two-tier plan: (1) defensive entry near €7.00 support with a stop below €6.80, (2) target €8.15 to €9.60 depending on momentum. Position sizing should reflect thin liquidity and market-cap risk. Use limit orders and track intraday volume to confirm follow-through.

Final Thoughts

Key takeaways for UOM.MU stock after the market-hours volume spike: price sits at €7.40, down -5.73%, on 9,750 shares traded on MUN (Germany). Fundamentals show EPS €0.57 and a conservative P/E 12.98, with book value per share near €8.55, which helps explain why the stock still attracts interest despite the drop. Meyka AI’s forecast model projects a 12‑month value near €8.15, implying an upside of 10.19% from the current price €7.40. Meyka AI’s forecast model projects these levels as model-based guidance rather than guarantees. Traders using a volume-spike strategy should monitor follow-through volume, test €7.00 support, and weigh limited liquidity. For company details and filings visit the official site and our stock page for real-time updates AS Latvijas Juras medicinas centrs website and Meyka stock page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.